Get the Stockscreener App
82.29
0.75%
0.61
Pre-market:
81.19
-1.10
-1.34%
Ani Pharmaceuticals Inc stock is traded at $82.29, with a volume of 284.52K.
It is up +0.75% in the last 24 hours and up +5.49% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$81.68
Open:
$82.16
24h Volume:
284.52K
Relative Volume:
0.79
Market Cap:
$1.87B
Revenue:
$923.71M
Net Income/Loss:
$84.68M
P/E Ratio:
20.88
EPS:
3.9419
Net Cash Flow:
$182.81M
1W Performance:
+2.70%
1M Performance:
+5.49%
6M Performance:
+0.96%
1Y Performance:
+31.54%
1-Day Range:
$81.25
$82.99
1-Week Range:
$80.75
$83.97
52-Week Range:
$62.14
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(609) 759-1810
Address
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
82.29 | 1.87B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock - Investing.com
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan - Stock Titan
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com India
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Director Jeanne Thoma receives 4,357-share grant at ANI Pharmaceuticals (ANIP) - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push - Yahoo Finance
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth - Yahoo Finance
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock - Investing.com UK
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock By Investing.com - Investing.com South Africa
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
[144] ANI PHARMACEUTICALS INC SEC Filing - Stock Titan
ANI Pharmaceuticals, Inc. $ANIP Stock Holdings Trimmed by Global Alpha Capital Management Ltd. - MarketBeat
ANIP (NASDAQ: ANIP) broker files Form 144 for 11,862-share sale - Stock Titan
How ANI’s Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Recall, Raised Guidance and Buybacks Could Mean For Shareholders - Sahm
ANI Pharmaceuticals Revenue Grows 20 Percent in Q1 2026 Financial Results - asatunews.co.id
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANI Pharmaceuticals Inc (ANIP) Stock Down 3.2% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program - MSN
ANI Pharmaceuticals (ANIP) Edges Higher: Approaching Key Resistance LevelsWeak Sell Signals - The Legal Advocate
ANI Pharmaceuticals (ANIP) expected to beat earnings estimates: Should you buy? - MSN
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Penn Capital Management Company LLC Increases Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals Holds Steady Near Support as Trading Volume EasesBreakout Confirmation - The Legal Advocate
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Precision Trading with Ani Pharmaceuticals Inc. (ANIP) Risk Zones - Stock Traders Daily
ANI Pharmaceuticals (ANIP) Q1 earnings: What to expect - MSN
ANI Pharmaceuticals (ANIP) Q1 2026 Earnings: Revenue Beat, Guidance, and Stock DropNews and Statistics - IndexBox
ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan - Stock Titan
Barclays Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem - Yahoo Finance
ANI Pharmaceuticals Q1 2026 earnings preview - MSN
Profitable Stocks: MYR Group & ANI Pharmaceuticals to Watch, B&G Foods to SellNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook - MSN
Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks - Barchart
How Raised 2026 Guidance And A New Buyback At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Yahoo Finance
ANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales Rise - Yahoo Finance
UBS Group AG Has $11.90 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook - TradingView
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Ani Pharmaceuticals Insider Sold Shares Worth $1,127,120, According to a Recent SEC Filing - Moomoo
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):